




Novel Cutting Edge Applications of Ion AmpliSeq[™] RNA Technology

Kelli Bramlett, Jeoffrey Schageman, Efren Ballesteros-Villagrana, Tom Bittick, Joel Brockman, Angie Cheng, Nathan Harris, Natalie Hernandez, Brian Sanderson, Daniel Williams, Susan Magdaleno, and Bob Setterquist, Life Technologies, 2130 Woodward Street, Austin, Texas, USA, 78744

ABSTRACT

Life Technologies recently released the first Ion AmpliSeq[™] offering for RNA which included a library construction kit as well as an integrated design system on Ampliseq.com. This platform allows researchers to simultaneously interrogate gene expression of up to 1200 targets in a single tube, thus combining the sensitivity of qPCR with sequence information gained from RNA sequencing. Since this launch, we have developed a program referred to as white glove to push the limits of what AmpliSeq[™] RNA currently offers. Here, we describe several examples of how these white glove initiatives have resulted in technological advances which will expand the repertoire of targeted RNA sequencing applications. We adapted our Ion RNA AmpliSeq[™] primer designer to enable design to multiple RNA transcript configurations addressing several biological phenomena. In particular, we have successfully designed and tested panels to investigate gene fusion detection in cancer, characterize B-cell receptor IgH stereotypes/mutational burden, and interrogate both cancer fusions as well as hotspot mutations in a single panel. In addition, we have developed software to design AmpliSeq[™] RNA fusion detection assays given COSMIC annotation. To facilitate easy reuse of AmpliSeq[™] RNA fusion primer designs, we created a database to store designs as they are created. Currently, this database contains over 400 fusion detection designs.

Detecting Lung Cancer Fusions in Cell Line and Human Tissue RNA



AmpliSeq[™] RNA Custom Design Project #3

Challenge:

Design a AmpliSeq[™] RNA panel that will detect specific fusion genes in addition to evaluating single nucleotide variants in well studies genes shown to be involved in oncogenic transformation.

The challenge in this project wa much molecular cytogenetic inf possible from very limited nucleic acid. The sample typ targeted RNA sequencing was limited number of precious ce from blood. In this case, the create one pool that would amp fusion genes from the ALK, RE⁻ families as well as provide coverage of the region of 36 and tumor supressor genes f mutational analysis. The 36 ger for hot spot mutation analysis v based on the content of AmpliSeq[™] Cancer Hotsp Because so few cells are reco blood following this uniqu enrichment method, there is r material for a DNA and a se AmpliSeq[™] library preparatio goal of this custom design targeted RNA designs to ide genes as well as obtain info hotspot mutations and gene information on the 36 targ suppressor and oncogenes.

		A549		And the party of the local division of the l	H1975		228	H3122	2	
		Contract of the local division of the local	and the second second		BC3	and the second second		BC5		HotSpot Genes
										and the second se
		0.034831			and the second distance	dinale				
	-	0.000470								
MET	_									JAK3 MET
IVIC I	_	200012000	1212	1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				a subscription of the second		
		CLASS SAMPLING						1000000		And the factor of the second se
		0.002443	45 0.0	0375067	0.004188	92 0.0	0393922	0.00	20703	STK11
			Contract of the local division of the	Configuration of a state of the	and the full sector for the sector		CONTRACTOR OF CONTRACTOR	and the second second	NO. OF THE OWNER OF THE OWNER	111.0.57
		No. of Concession, Name		Manufacture and and and and		and the second second	ACCOUNT OF A DESIGNATION OF A DESIGNATIONO OF A DESIGNATIONO OF A DESIGNATIONO OF A DESIGNA		Contraction of the local division of the loc	and the second
	-					1 3 mouth	In the second	and the second second	COCK CONSTRUCT	CTNNB1
FLT1					A Print and a state of the stat	and the second	and the second second second	and the second second		FLT1
		0.000382	25 0	0004962	0.001965	48 0.0	00160212	0.001	51124	KDR
			and the second second	A DESCRIPTION OF THE OWNER OF THE			The second states with	and the second second		NTRK1
		ite Mantaladadan ha	Robell Been	NG CARACTERIZATION OF COMPANY				Contraction of the local	And the second second second	
	_									aper last
		and the second			A DESCRIPTION OF THE OWNER OF THE					
										and the second se
		Contraction of the local division of the loc	State of State of State	and the second	and the second second					
EZH2		0.031123	84 0.0	6265385	0.023040	05 0.0	2335205	0.021	29214	EZH2
										and the second se
EGFR		Bearing and a state of the	0.000		End for Delay Grades		A MARCO SALES	Checklosins.	A Britshad	and the second sec
										and the second second
					Conception of the local division of the loca		State of the state	Contraction of the local distance of the loc	the second second	and the local data in the loca
	_	CALIFORNIA CONTRACTOR	owners and the owner where	And the owner of the owner.	and the boundary of the second			and the second second		and the second s
		0.000548	38 0	0004589	0.000119	06 0.0	00025709	0.000	15146	PDGFRA
	_	0.00215	97 0.0	0496197	0.004380	41 0	.0095343	0.004	02367	PIK3CA
				ALL DOG BOOM DOG BOOM						and the second
	_	Craft Contraction Con	and the second		All the formation with	Information of the		Contractor Contractor	CONTRACTOR OF THE OWNER	
RET	-				NAME OF TAXABLE PARTY.			and the second second	The state of the s	stand and some statements of the
0.00161867 0.00506185 0.02405077 0.10938773 0.00054838 0.0021597 0.0021597 0.0021597 0.0021597 0.0021597 0.00245234 RET 0.0024552 0.03210592 0.00409006 total A549 0 0 0 0 0 0 0 0 0			NAME OF TAXABLE PARTY OF TAXABLE PARTY.		The second s	a subscription of the	Contraction of the			
		and a second second second						and the second second second		and the second statement of the se
total					polvA+					
				H3122	A549 I					1
e 0		0 0	0	0	0	0	0	0	(0
-				0	0	0	0	0		0
-			0	0	0	0	0	0		0
0		0 0	0	0	0	0	0	0		0
0			-	0	0	0	0	0	(0
-			0	0	0	0	0	0		0
-		-		0	0	0	0	2		0
0		0 0	0	16	0	0	0	0	20	0
				0	0	0	0	0		0
-			0	0	0	0	0	0		0
0		0 0	0	0	0	0	0	0	(0
0		0 0	0	0	0	0	0	0		0
0		0 0	0	0	0	0	0	0		0
0		0 0	0	0	0	0	0	0		0
0						0	-	-		-
0		0 0 0 0 0	0	0	0	0	0	0		0
0		0 0	-	0	0	0	0	0	(0 0
		0 0 0 0 0 0 0 0 0 0 0 0	000000000000000000000000000000000000000	0 0 0 0 0 0	0	0 0 0	0	0		0 0 0
		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000000000000000000000000000000000000000	0 0 0 0 0	0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0		0 0 0 0
		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000000000000000000000000000000000000000	0 0 0 0 0	0 0 0 0 0 0	0 0 0 0	0 0 0 0 0	0 0 0 0 0		0 0 0 0 1
	MET MET FLT1 FLT1 EGFR RET RET 0	BC/LC Image: Strate in the strate i	BC/LC A549 BC6 0.01230 0.034831 0.034831 0.034831 0.034831 MET 0.072869 MET 0.072869 0.010742 0.01903 0.036922 0.01903 0.0191257 0.001443 0.0191257 0.01145 0.000382 0.000382 FLT1 0.001145 0.000303 1.4702E 0.000303 0.000213 0.0000320 0.000213 0.000320 0.000320 EZH2 0.001618 0.000320 0.0005061 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.00215 0.0005061 0.000 0 0 0		BC/LC A549 MCF7 BC6 BC2 0.0123084 0.01495079 0.03483165 0.01763771 0.000047928 0.00016702 MET 0.07286977 0.0080251 0.0190345 0.02855405 0.0190345 0.02855405 0.0190345 0.02855405 0.0190345 0.02855405 0.0190345 0.02855405 0.0190345 0.02855405 0.01074265 5.9988E-05 0.14164802 0.08554379 0.19125798 0.14965966 FLT1 0.00114527 0.0018502 0.00202151 0.002838 0.00058538 0.00202151 0.00128914 0.001021779 0.0134249 0.000121779 0.0134249 0.0002638 0.00297566 EGFR 0.06717574 0.00224424 0.00161867 0.00297566 0.002050185 0.1345733 0.10938773 0.13529002 0.000245838 0.00045838	BC/LC A549 MCF7 H1975 BC6 BC2 BC3 0.0123084 0.01495079 0.011514 0.03483165 0.01763771 0.00399 0.00047928 0.00016702 0.000763 0.00047928 0.00016702 0.000763 MET 0.07286977 0.0080251 0.075313 0.00244345 0.00375067 0.004188 0.00303522 0.05179101 0.06618 0.019125798 0.14969596 0.138121 FLT1 0.00114527 0.0018802 0.0001188 0.00030359 0.03758128 0.049754 0.00021318 0.00028538 3.6718 0.000202151 0.00128914 0.001244 0.000202151 0.00128914 0.001244 0.00011779 0.0134249 0.00234 0.0002158 0.0024426 7.14368 0.00030259 0.0024424 0.003037 EGFR 0.06717574 0.0024423 0.003873 EGFR 0.06717574 0.0024423	BC/LC A549 MCF7 H1975 H2 BC6 BC2 BC3 BC 0.0123084 0.01495079 0.01151407 0.0 0.00047928 0.00016702 0.00075397 0.4 0.00047928 0.00016702 0.00075397 0.4 0.0103435 0.02855405 0.0041892 0.0 0.01090345 0.028554379 0.0431892 0.0 0.01074265 5.9998E-05 0 0 0 0.01014527 0.0018502 0.0011807 0.0 0.0 0.14164802 0.08554379 0.08537976 0.1 0.0 0.00030259 0.03758128 0.04975409 0.0 0.0 0.00021318 0.0002838 3.671E-05 0.0 0.0 0.0 0.00021318 0.00024538 0.00294653 0.0023418 0.0 0.0 0.00021318 0.00024853 3.671E-05 0.0 0.0 0.0 0.00021318 0.00024485 0.00234065 0.0 0.0	BC/LC A549 MCF7 H1975 H2228 BC6 BC2 BC3 BC4 0.0123084 0.01495079 0.01151407 0.02016814 0.03483165 0.01763771 0.4039996 0.66421415 0.00047928 0.00016702 0.0007397 0.00023135 MET 0.07286977 0.000251 0.07251336 0.13415846 0.0109345 0.0255405 0.00418892 0.00399222 0.0109345 0.0255407 0.0418892 0.0039322 0.01074265 59998E 05 - 1.162-05 0.14164802 0.08554379 0.08537976 0.4022706 0.14164802 0.005828 3.671-05 0.0008274 0.00030359 0.03758128 0.04975409 0.01589485 0.0002151 0.0014827 0.0018258 0.0013218 0.00290505 0.0013218 0.0002151 0.00148274 0.00128148 0.0013218 0.0029050 0.00357285 EV11 0.0024538 0.0024538 0.0214573 0.0014318	BC/LC A549 MCF7 H1975 H2228 H3122 BC6 BC2 BC3 BC4 BC5 0.0123084 0.01495079 0.01151407 0.02016814 0.012 0.003483165 0.01763771 0.00039996 0.06421415 0.020 0.00047928 0.00016702 0.00076397 0.00072335 0.000 MET 0.07285977 0.0020551 0.07251336 0.0348366 0.086 0.00047928 0.0007507 0.00431096 0.0029799 0.03 0.01074265 5.99986-05 0 1.1672-05 4.45 0.10124527 0.0018502 0.0011807 0.0038422 0.001 0.14164802 0.08534797 0.0038422 0.001 0.0021807 0.001220 0.001 0.14164802 0.00254540 0.019548 0.0010318 9.68 0.0010313 9.68 0.14162802 0.0022451 0.00135387 0.0103133 9.68 0.0010313 9.68 0.00202151 0.001259998 0.00241	BC/LC A549 MCF7 H1975 H2228 H3122 BC6 BC2 BC3 BC4 BC5 0.0123084 0.01495079 0.01151407 0.02016814 0.01236833 0.03483165 0.0176377 0.04039996 0.6421415 0.02625685 0 0 0.00118068 0 1.1137E.06 0.00047928 0.00016702 0.00772335 0.00225057 MET 0.07286977 0.0080251 0.0721360 0.0022033 0.00149035 0.02854350 0.00431096 0.0029799 0.0301157 0.0024345 0.0035506 0.0418892 0.0020703 0.0020703 0.01074255 5.99986.05 0 1.1627.05 4.4547606 0.19125798 0.1495595 0.13812126 0.00284763 0.022777 0.0003825 0.0004962 0.0011807 0.0028476 0.02287639 0.11422705 8.107840 0.01589485 0.03098324 0.00030359 0.00290505 0.0013031 0.00243451 0.02257

INTRODUCTION

RNA-seq experiments have traditionally started with a whole-transcriptome library preparation that produces a sequencing template from all RNA species in a sample. However, in many cases, only a handful of the genes present are necessary to make a statistically significant conclusion confirming a hypothesis, validating expression data derived from an orthologous platform, or informing a clinical treatment decision.

We have demonstrated new technology that allows for targeted RNA-seq from a panel of directed amplicons using Ion AmpliSeq[™] technology with Ion Torrent[™] semiconductor sequencing. This approach offers many advantages over microarray or qPCR data such as faster turnaround and data analysis, sample multiplexing, lower RNA inputs, and ability to use degraded or FFPE-derived samples. In addition, the technique simultaneously provides digital, quantitative gene expression information and gene sequence at the single nucleotide level. This capability enables not only gene expression measurements, but also identification of fusion genes as well as gaining nucleotide level information along the designed amplicon enabling single nucleotide variant identification. Here, we describe unique applications of this targeted RNA sequencing approach taking advantage of some of these capabilities by sequencing RNA in a custom designed and targeted fashion.

MATERIALS AND METHODS

The White Glove RNA AmpliSeq^(TM) process requires an application be completed describing the detailed technical needs of this targeted RNA sequencing approach. We then custom design AmpliSeq RNA primers for each customer to meet the specific experimental aims. Additionally, we provide analysis recommendations and the appropriate reference files needed to calculate the number of sequencing reads that align to each custom designed oligo.

EML4/ALK fusion identified in patient lung tumor FFPE sample

SLC34A2/ROS1 fusion identified in HCC78 cell line

After determining the sensitivity of the AmpliSeq[™] RNA fusion panel sensitivity to be ≤ 1% fusion containing RNA, we expanded the testing to include other cell line RNA and human tissue RNA harboring previously characterized fusion genes. As shown in the graph above we were able to successfully detect a second EML4-ALK fusion in RNA isolated from human tissue that was formalin fixed paraffin embedded (FFPE). Additionally, we successfully amplified a fusion gene from different fusion partners, SLC34A2 and ROS1 from HCC78 cell line total RNA.


AmpliSeq[™] RNA Custom Design Project #2


Challenge:

Create a custom RNA AmpliSeq design to determine the dominant B cell Receptor Prototype as well as mutational burden of the variable region (V_H) of the receptor

A seminal publication from 1998 by Fais et al. describes the analysis of rearranged V_H genes expressed by B-type chronic lymphocytic leukemia (B-CLL)cells and the mutations within the V_H family (5). This publication describes primers to amplify long amplicons to determine the correct V_H family assignment, D and J_H sequence identification, and analysis of HCDR3 rearrangements by cDNA sequencing from 1 µg of RNA. We attempted to create custom designed AmpliSeqTM RNA primers to amplify the V_H , D and J_H regions of the B cell receptor in one multiplexed amplification reaction requiring only 5 ng of total RNA.

The original strategy outlined in Fais et al. targets the V_H sequence with the forward primer and the IgM sequence with the IgM primer:





AmpliSeq[™] RNA Custom Design Project #1


Challenge:

Create a custom RNA AmpliSeq design for a complete analysis of RNA fusion genes implicated in lung cancer.

Historically, the fluorescent in situ hybridization (FISH) technique has been widely employed to study genomic variation in malignant cells. Recently the field of molecular cytogenetics is investigating next generation sequencing technologies to get even more complete information about the genomic variation in malignancies (1). Recently a gene fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) was identified in a NSCLC patient with a smoking history leading to a phase I clinical trial with an inhibitor of ALK (2,3). Subsequently, additional genes have been identified to be involved in lung cancer and targeted for potential for therapeutic intervention, such as RET and ROS1 (4). The FISH technique is labor intensive and experimentally demanding limiting the number of individual fusion genes that can be reasonably assayed for in any given sample. Due to the inherent limitations of FISH and the increased identification of chimeric fusion kinases with potential for oncogenic transformation the desire was to find a technology that would allow for testing for multiple fusion genes with limited tissue. With the new advancements in targeted RNA sequencing, we attempted to design a single panel targeting over 40 fusion genes involving ALK, RET and ROS1. Testing tissue samples for these fusion genes can be accomplished in one amplification reaction from as little as 5 ng of FFPE RNA.




However, this produces amplicons too long for RNA AmpliSeq. We used the following strategy for detecting V_H families and for typing the D and J regions:



Here amplicons from forward and reverse primers 1 determine the family type, while amplicons from forward and reverse primers 2 determine the D and J type.

Library construction results:



Using the design strategy highlighted above, we created a multiplexed AmpliSeqTM RNA primer pool that would provide receptor typing information as well as mutational analysis capabilities of the V_H region of the B cell receptor. We received 4 B-CLL RNA samples from our customer and successfully created targeted RNA sequence libraries as shown by the Agilent2100 Bioanalyzer traces above. Although the yield was low for sample B, C, and D, we were able to get viable libraries in sufficient quantity for template prep and sequencing on the Ion Torrent PGM 318TM Chip. We also identified a unique data analysis tool that proved incredibly helpful in evaluating the resulting amplicon information. This analysis tool, IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/) was developed specifically to map sequencing reads to the V_H, D, and J domains of the B cell receptor and also display the variants identified in reads mapping to the VH region (6). Using this tool on 1000 reads of each of the 4 RNA libraries we were able to see significant alignments to the reference available with the online IgBLAST tool. For sample A-300903, we also identified the predominant B Cell Receptor form.

Dvoro (Poellion a		No			Gen X 1			Target 10			Type I	
Zyposity a Var Freq c												
G Dream Poster	Same Byrn	Target D	Type	Zyperty	Gerutpe	Ber.	Variant	Var Free	Q.at	Cav .	Ref Car	the Cav.
@ NM_00_ 1842	168.	NR	5NP	1960	10C	π.	¢	45.8%	36.07	24	18	. 11
0 NM_00. 8044	546	368	310	Per .	GA	. 6	Α.	40,0%	28.22	25	16	10
B NM_00 3758	76.0	164	OBL	Hum	Aph	AG	Α.	100.0%	100	72	0	- 11
B NM.00. 720	345	365	510	746	¢#	0	T	27.8%	84.05	400	289	111
@ NM_00_ 1968	164	264	25P	140	GiA	6	Α.	23.3%	21.14	43	33	210
@ NM_00. 2153	168	365	398	796	TIA	T	A	33.6%	100	399	265	134
@ NM_00_ 2447	260.	3634	84*	repre	AA	0	Α	100.0%	100	181	0	185
(3 NM_00_ 1986	168.	3436	06.	man	CC.	CITAA	0	150.0%	100	389	0	288
the last the stant	603	10.00	1040	incer.	THE	-05	T	100.0%	466	44		41

CONCLUSIONS –

Barcode

Sample Nat

Library Type

Total calls > Het SNPs

> Hom SNPs > Het INDELs


Hom INDELs
 Other variants
 No Calls + Reference Co

The AmpliSeq[™] RNA custom design "white glove" process has been utilized for unique applications of targeted RNA sequencing technology. Being able to get quantitative gene expression information in addition to detect fusion transcripts and single nucleotide variants within the targeted amplicon is ideal for some of the unique applications described here.

- White Glove custom design capabilities are available to meet individual experimental goals with AmpliSeq[™] RNA technology
- This process provides custom primer design as well as specific reference and analysis files with guidance on recommended analysis methods
- Through white glove design species other than human can also be amplified in a targeted fashion
- As little as 5 ng of total RNA is required for AmpliSeq[™] RNA sequencing of up to 1200 targets
- This technology is ideal for fusion gene detection alone or in combination with gene expression measurements and mutation analysis

REFERENCES

- 1. Das K, Tan P. Molecular cytogenetics: recent developments and applications in cancer. *Clin Genet* 2013: 84: 315-325.
- Stephens PJ, Tarpey PS, Davies H et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature 2007: 448: 561-566.*
- 3. Kimura H, Nakajima T, Takeuchi K et al. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. *Lung Cancer 2012: 75: 66-72*.
- Gainor J, Shaw A. Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions. The Oncologist 2013: 18: 865 – 875.
- 5. Fais F, Ghiotto F, Hashimoto S et al. Chronic Lymphocytic Leukemia B Cells Express Restricted Sets of Mutated and Unmutated Antigen Receptors. *J Clinical Invest 1998: 102: 1515-1525.*
- 6. Ye J, Ma N, Madden TL, and Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. *Nucleic Acids Res 2013: 41: 34-40.*



Tested using Human Brain Reference RNA (HBR) and H2228


 (H2228 = Lung cancer adenocarcinoma cell line expressing EML4-ALK fusion transcript variant 3)

Mix H2228 RNA into HBR RNA

• 100%, 50%, 15%, 5%, 1%


Readily detect presence of fusion in 99% normal RNA

To determine the sensitivity of detection of this custom designed AmpliSeq[™] RNA panel, we used a well characterized cell line H2228 containing a known EML4-ALK. We successfully detected this EML4-ALK variant when only 1% of the total RNA used in the library procedure was from the fusion gene containing H2228 cell line in the background of the Human Brain Reference (HBR) RNA.



 Number
 Num
 Num
 Num

V, D, and J regions summary - 300903 (BC25)



 chain type
 stop codon
 V-J frame
 Productive
 Strand

 VH
 NO - 408
 In-frame - 294
 NO - 193
 neg - 198

 YES - 54
 Out-of-frame - 164
 YES - 265
 pos - 264

IGHV2-74*03 IGHD3-10*01 IGHJ6*02

ACKNOWLEDGMENTS

We would like to thank Tom Bittick, the product manager for AmpliSeq[™] RNA products and the White Glove Design team for AmpliSeq[™] DNA for valuable insight and discussion. We also appreciate the

TRADEMARKS/LICENSING

For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.

Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners

For Research Use Only. Not for use in diagnostic procedures. ©2013 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation and/or its affiliate(s) or their respective owners.

Life Technologies • 5791 Van Allen Way • Carlsbad, CA 92008 • lifetechnologies.com